- Home
- ACOG vs ADVM Comparison
ACOG vs ADVM Comparison
Compare ACOG & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACOG
- ADVM
- Stock Information
- Founded
- ACOG 2000
- ADVM 2006
- Country
- ACOG Canada
- ADVM United States
- Employees
- ACOG N/A
- ADVM N/A
- Industry
- ACOG
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACOG
- ADVM Health Care
- Exchange
- ACOG Nasdaq
- ADVM Nasdaq
- Market Cap
- ACOG 91.6M
- ADVM 98.0M
- IPO Year
- ACOG N/A
- ADVM 2014
- Fundamental
- Price
- ACOG $4.12
- ADVM $2.93
- Analyst Decision
- ACOG Strong Buy
- ADVM Strong Buy
- Analyst Count
- ACOG 1
- ADVM 6
- Target Price
- ACOG $20.00
- ADVM $25.83
- AVG Volume (30 Days)
- ACOG 75.4K
- ADVM 176.5K
- Earning Date
- ACOG 05-20-2025
- ADVM 04-15-2025
- Dividend Yield
- ACOG N/A
- ADVM N/A
- EPS Growth
- ACOG N/A
- ADVM N/A
- EPS
- ACOG N/A
- ADVM N/A
- Revenue
- ACOG N/A
- ADVM $1,000,000.00
- Revenue This Year
- ACOG N/A
- ADVM $1,187.80
- Revenue Next Year
- ACOG N/A
- ADVM N/A
- P/E Ratio
- ACOG N/A
- ADVM N/A
- Revenue Growth
- ACOG N/A
- ADVM N/A
- 52 Week Low
- ACOG $3.75
- ADVM $2.89
- 52 Week High
- ACOG $7.00
- ADVM $11.87
- Technical
- Relative Strength Index (RSI)
- ACOG N/A
- ADVM 31.79
- Support Level
- ACOG N/A
- ADVM $3.07
- Resistance Level
- ACOG N/A
- ADVM $3.71
- Average True Range (ATR)
- ACOG 0.00
- ADVM 0.46
- MACD
- ACOG 0.00
- ADVM -0.12
- Stochastic Oscillator
- ACOG 0.00
- ADVM 9.20
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a commercial-stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI), for which there are currently no approved treatment options.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.